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JAK/STAT3 regulated global gene
expression dynamics during late-stage
reprogramming process
Ling Wang1†, Zongliang Jiang1,4†, Delun Huang1,2, Jingyue Duan1, Chang Huang1, Shannon Sullivan1, Kaneha Vali1,
Yexuan Yin1, Ming Zhang2, Jill Wegrzyn3, Xiuchun ( Cindy) Tian1* and Young Tang1*

Abstract
Background: The generation of induced pluripotent stem cells (iPSCs) has underdefined mechanisms. In addition,
leukemia inhibitory factor (LIF) activated Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3)
pathway is the master regulator for naïve-state pluripotency achievement and maintenance. However, the regulatory
process to attain naïve pluripotent iPSCs is not well understood.
Results: We performed transcriptome analysis to dissect the genomic expression during mouse iPSC induction, with
or without blocking the JAK/STAT3 activity. We describe JAK/STAT3 signaling-specific biological events such as
gametogenesis, meiotic/mitotic cell cycle, and DNA repair, and JAK/STAT3-dependent expression of key transcription
factors such as the naïve pluripotency-specific genes, developmental pluripotency associated (Dppa) family, along with
histone modifiers and non-coding RNAs in reprogramming. We discover that JAK/STAT3 activity does not affect early
phase mesenchymal to epithelial transition (MET) but is necessary for proper imprinting of the Dlk1-Dio3 region, an
essential event for pluripotency achievement at late-reprogramming stage. This correlates with the JAK/STAT3dependent stimulation of Dppa3 and Polycomb repressive complex 2 (PRC2) genes. We further demonstrate that JAK/
STAT3 activity is essential for DNA demethylation of pluripotent loci including Oct4, Nanog, and the Dlk1-Dio3 regions.
These findings correlate well with the previously identified STAT3 direct targets. We further propose a model of
pluripotency achievement regulated by JAK/STAT3 signaling during the reprogramming process.
Conclusions: Our study illustrates novel insights for JAK/STAT3 promoted pluripotency establishment, which are
valuable for further improving the naïve-pluripotent iPSC generation across different species including humans.
Keywords: Reprogramming, iPSC, LIF, STAT3, Pluripotency, Gametogenesis, Dlk1-Dio3, Imprinting, DNA methylation

Background
Generation of induced pluripotent stem cells (iPSCs)
represents a powerful way to establish embryonic stem
cell (ESC)-like cells through ectopic expression of the
four transcription factors, namely Oct4, Klf4, Sox2, and
c-Myc (OKSM) [1]. However, its mechanism is not
completely understood. This hinders further effort to
improve the reprogramming efficiency and general safety
of human iPSCs for clinical applications. Early mechanistic studies revealed that a mesenchymal to epithelial
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transition (MET) is required for successful reprogramming [2, 3]. Large-scale transcriptome and epigenomic
analysis further revealed a multi-step reprogramming
process, where somatic cells undergo an initiation/MET
phase, followed by an intermediate phase characterized
by stochastic activation of pluripotent markers and transient upregulation of developmental genes. Subsequently, the reprogrammed cells enter a late maturation/
stabilization phase hallmarked by silencing of transgenes
and activation of core pluripotent circuitry, to form
completely reprogrammed, pluripotent iPSCs [3–7]. The
entire reprogramming process is also characterized by
epigenetic changes such as histone H3 lysine (K) acetylation and methylation, DNA demethylation or de novo
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methylation, to activate the core pluripotency genes, and
poise reprogrammed cells for differentiation under developmental cues [4, 6, 8, 9]. However, to date, a complete
understanding to pluripotency establishment at latereprogramming stage has not been achieved.
The transition of somatic to pluripotent state is also
regulated by stage-specific expression of non-coding
RNAs such as microRNAs (miRNAs) [4, 8, 10, 11] and
long intervening non-coding RNAs (lincRNAs) [9, 12–
14], to regulate the expression of pro-differentiation and
metabolic processes. The activation of maternally
expressed lincRNA cluster Gtl2-Rian-Mirg, localized in
the Dlk1-Dio3 region at chromosome 12qF1 (Additional file 1), is essential for full pluripotency in mouse
iPSC generation. Improper imprinting of this region is
associated with poor chimera capacity of iPSCs and
compromised generation of viable iPSC-mice by tetraploid complementation [15–17]. The expression of the
Gtl2-Rian-Mirg is controlled by the intergenic differential methylated region (IG-DMR) localized between Dlk1
and Gtl2 genes [18] (Additional file 1). This region is
hypermethylated at late-reprogramming stage [15], and
only a small portion of iPSCs could re-establish proper
imprinting of this region (~ 50% methylated IG-DMR)
and become truly pluripotent [16, 17]. Vitamin C or the
developmental pluripotency associated 3 (Dppa3) gene
antagonize the binding of de novo DNA methyltransferases 3 (Dnmt3s) to IG-DMR region, therefore prevent
the IG-DMR hypermethylation in reprogramming [15,
19]. Polycomb repressive complex 2 (PRC2) also
antagonize Dnmt3s for proper imprinting of Dlk1-Dio3
in mouse ESCs [20]. However, how Dppa3 or PRC2 activity is controlled in reprogramming to ensure proper
imprinting of the Dlk1-Dio3 region is unclear.
The cytokine leukemia inhibitory factor (LIF) activates
Janus kinas/signal transducer and activator of transcription 3 (JAK/STAT3) pathway by inducing heterodimerization of LIF receptor and the signal transducer protein
gp130 [21, 22]. Activation of JAK/STAT3 by LIF ensures
naïve-state mouse ESC pluripotency and self-renewal
[23–27]. STAT3 also plays a key role in naïve-state iPSC
generation [28–30]. However, the question remains
how exactly JAK/STAT3 activity regulates different
biological events to ensure complete reprogramming.
Characterization of JAK/STAT3 mediated reprogramming
activities is needed to fully elucidate its downstream
mechanism/effectors for naïve-state pluripotency generation. Such knowledge will also help to improve the LIF
signal-dependent naïve-state iPSC generation across different species including humans [31].
We previously showed that enhancing STAT3 activity
in reprogramming promotes pluripotency establishment
from mouse embryonic fibroblasts (MEFs), while blocking JAK/STAT3 activity only leads to partially
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reprogrammed pre-iPSCs [29]. These pre-iPSCs failed to
silence the OKSM transgenes and to activate key pluripotent genes such as Oct4 and Nanog [29], two hallmarks of late-stage reprogramming [3–7]. To further
understand the regulatory role of JAK/STAT3 in latestage reprogramming, we performed transcriptome analysis to those reprogrammed cells at two different time
points, and identified biological events specific to JAK/
STAT3 signaling. We further discovered that JAK/
STAT3 regulates proper activation of the imprinted
Dlk1-Dio3 region in reprogramming. Our study unveils
novel mechanisms for LIF/STAT3 regulated late-stage
reprogramming process.

Results
RNA-seq analysis reveals dynamic global gene expression
between two different reprogramming stages regulated
by JAK/STAT3 activity

We performed transcriptome analysis of the RNA samples of reprogrammed MEFs that carry a GFP reporter
controlled by the Oct4 distal enhancer region (OGMEFs), as described previously [29] (Fig. 1, GEO accession number GSE97261). Briefly, OG-MEFs were seeded
on day minus one (D-1), transduced with retroviral
OKSM on the next day (D0) and then cultured in LIFcontaining reprogramming medium, with the addition of
either control DMSO (Ctl) or 1 μM specific Jak inhibitor
I (Jaki) [32, 33] starting on Day 3 (D3). RNAs were
extracted from the D18 reprogrammed cells (named
DMSO-Stage 1 (S1) or Jaki-S1, respectively), or from
induced colonies picked on D21 and expanded one more
passage (p2) (named DMSO-Stage 2 (S2) or Jaki-S2,
respectively) (Fig. 1). We chose these two time points
(S1 and S2) to identify global gene expression differences
between Ctl and Jaki-treatments, since the GFP positive
(GFP+) colonies (indication of endogenous Oct4 activation) in Ctl reprogrammed cells started to develop
quickly between S1 and S2, while those colonies in Jakitreatment remained GFP negative (GFP-) [29]. Pearson
correlation coefficient and clustering analysis of all
detected transcripts by RNA-seq (FPKM > 0.1) illustrated significant difference in global gene expression
patterns between the S1 and S2 reprogrammed cells
(Fig. 1b, c). These data show that dynamic change of global gene expression happened between S1 and S2. In
addition, clustering analysis classified the Jaki- and
DMSO-treated cells into different groups within each
stage (Fig. 1c). We also performed principle component
analysis (PCA) to all detected genes across our samples.
Plots using the two most significant principle components further confirmed the differences between S1 and
S2 reprogrammed cells, and between the DMSO Ctl and
Jaki-treated cells within each stage (Fig. 1d). Thus, S1
and S2 samples represent reprogrammed cells at two
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Fig. 1 Dynamic Gene Expression Changes at Two Different Reprogramming Stages. a Schematic diagram depicting the reprogramming process
and dates for RNA sample collection from reprogrammed cells. b Pearson Correlation of the duplicated samples of different reprogramming
conditions and stages. The colored bar along the right side of the heatmap indicates the Pearson’s correlation coefficient. c Hierarchical clustering
of differentially expressed genes among different treatments and reprogramming stages. The relative abundance is represented by color (red,
lower abundance; green, higher abundance), as indicated by the color key. d PCA analysis to the transcriptomes of different reprogramming
samples. PC1 and PC2 represent the top two dimensions of the differentially expressed genes. e Bar chart representing the numbers of up- or
down-regulated DEGs between S1 and S2 and between two treatments at the same reprogramming stage
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distinct stages, and that inhibiting JAK/STAT3 activity
significantly impacts global gene expression patterns at
either stage.
We further analyzed the differentially expressed genes
(DEGs) either 1) between the S1 and S2 reprogrammed
cells within each treatment, to compare the dynamic reprogramming differences in Ctl (undisturbed JAK/STAT3
signaling) and Jaki (blocked JAK/STAT3 signaling) conditions, or 2) between the Jaki- and DMSO-treatments at S1
or S2, to identify specific targets of JAK/STAT3 activity at
these two reprogramming stages. Out of the 13,547 genes
detected, Cuffdiff analysis revealed the largest numbers of
significantly up−/down-regulated genes (1500/1656, fold
change > 1.62×) happened in Ctl reprogramming between
S2 and S1 (Fig. 1e, Additional file 2). Whereas the smallest
numbers of significantly up−/down-regulated genes (40/
170) were found between the Jaki- and DMSO-treatment
at S1, there are 969/781 up−/down-regulated DEGs identified at S2 (Fig. 1e, Additional file 2). The sharp contrast
in the numbers of DEGs at S1 and S2 between Jaki vs.
DMSO-treatment supports the notion that JAK/STAT3
plays a more significant role for pluripotency establishment at late-reprogramming stage, and correlates with the
previous reports that STAT3 functions for naïve-state induction from pre-iPSCs and primed-state epiblast stem
cells, as well as for the self-renewal of ESCs [29, 34–36].
JAK/STAT3 regulates specific biological events between
the two reprogramming stages

We then asked how JAK/STAT3 signaling specifically
regulates the reprogramming events. For all significantly
upregulated DEGs from S1 to S2 in either Ctl- or Jakitreatment, 351 were commonly upregulated under both
treatments, 1149 were specifically upregulated in Ctl reprogramming, while 249 genes were upregulated only
in Jaki-treatment (Fig. 2a–left). These common or
specific DEGs were subject to gene ontology (GO)
analysis using the DAVID platform [37], with similar
GO-terms for biological processes (BPs, false discovery rate (FDR) < 0.05) grouped together to illustrate
reprogramming events under these conditions (Additional file 3). Multiple upregulated events from S1 to
S2 common for both Jaki- and Ctl-treatments were
identified (Fig. 2b–left). These include the protein
translation, redox process, nucleosome assembly/transcription regulation, and negative regulation of megakaryocyte differentiation. The latter two BPs are
characterized by upregulation of genes from various
histone subfamilies, including H1H1, H2B1, H2B2,
H3A1, H41, and H44 (Additional file 3). On the other
hand, activation of events like mitotic cell cycle,
spermatogenesis/meiotic cell cycle, and the DNA repair process that is intrinsically associated with different phases of cell cycle [38], are only observed in Ctl
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reprogramming (Fig. 2b–right, Additional file 3). The
protein modification processes were also upregulated
in Ctl reprogramming, and over-represented by DEGs
either for protein folding, such as the FKBP family
(FKBP3–6, − 11) and the CCT family (CCT2–4, −6A,
− 7) [39, 40], or for protein sumoylation, such as
Sumo1, Sumo2, and the E3 SUMO-protein ligase
Pias2 [41] (Fig. 2b–right, Additional file 3). However,
no significant GO-term was found from the 249 upregulated DEGs under Jaki-treatment (Fig. 2a–left,
and data not shown).
For all significantly downregulated DEGs between S2
and S1 reprogrammed cells, 481 genes were commonly
downregulated in both Ctl- and Jaki-treatments, while
1175 and 475 genes were specifically downregulated in
Ctl- or Jaki-treatment, respectively (Fig. 2a–right, Additional file 3). GO-analysis of those groups of DEGs revealed commonly downregulated biological events from
S1 to S2 reprogramming in both Ctl- and Jakitreatments (Fig. 2c–top). These include cell adhesion
and migration, positive regulation of transcription, cell
differentiation such as endo−/meso-dermal development, VEGF signaling, response to estradiol, and cell
proliferation. However, the downregulation of cellular
immune response and protein phosphorylation process
from S1 to S2 can only be observed in Ctl- but not Jakitreatment (Fig. 2c–lower left and right, Additional file
3). Thus, these data reveal that multiple biological events
associated with undisturbed JAK/STAT3 signaling happen during reprogramming. These include the upregulation of gametogenesis, meiotic/mitotic cell cycle, and
protein modification including protein folding and
sumoylation, and downregulation of immune responses
and protein phosphorylation.
JAK/STAT3 is critical for activation of gametogenesis and
meiotic cell cycle event genes in reprogramming

To further evaluate the biological events in reprogramming that are JAK/STAT3-specific, we compared the
DEGs between Jaki- and Ctl-treatments at the same reprogramming stage. As there are limited numbers of significant DEGs identified at S1 (Fig. 1e), we focused on
analyzing the DEGs at S2 between Ctl- and Jakitreatments. Surprisingly, out of the 969 upregulated
genes between these two conditions at S2 (Fig. 1e), only
one significant GO-term was identified - negative regulation of RNA polymerase II promoter activity (Additional file 4). On the contrary, GO-analysis to
downregulated genes between Ctl- and Jaki-treatments
at S2 revealed significant BPs that fall into five categories: cell cycle and DNA replication, meiotic cell cycle
and spermatogenesis, DNA damage response and repair,
regulation of gene expression, and stem cell maintenance (Fig. 3a, Additional file 4). Interestingly, the first
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Fig. 2 JAK/STAT3 Regulates Specific Biological Events in Reprogramming. a Venn Diagrams for common or specific up- (left) or down- (right)
regulated DEGs between S1 and S2 under either DMSO or Jaki condition. b Pie charts for summarized GO-terms using DEGs upregulated commonly
between S2 and S1 (left), or upregulated in Ctl reprogramming only (Ctl-specific) (right). The number of DEGs with GO terms vs. the total number of
DEGs under each comparison was shown under each chart. c Pie charts for summarized GO-terms using DEGs downregulated commonly between S2
and S1 (top), downregulated in Ctl reprogramming only (lower left), or in Jaki-specific (lower right) condition. The number of DEGs with GO terms vs.
the total number of DEGs under each comparison was shown under each chart

three categories of events downregulated here were
also upregulated from S1 to S2 in Ctl reprogramming
(Fig. 2b–right). We wondered whether this indicates
an up- or down-regulation of the same group of
genes during the Ctl S1 to S2 reprogramming or in
Jaki- vs. Ctl-treatment at S2, respectively. In fact,
comparing the DEGs listed in each category revealed
a significant portion of overlapped genes upregulated
from S1 to S2 in Ctl reprogramming but downregulated
by Jaki-treatment at S2 (Fig. 3b, Additional file 5). For example, out of the 69 meiosis and spermatogenesisrelevant genes upregulated in Ctl reprogramming, 29
(such as Text19.1, Mael, and Syce1/2 [42–45]) were downregulated at S2 by Jaki-treatment (Fig. 3b–upper left,
Table 1). Similar cases were found for the genes regulating mitosis (34 out 160, such as Aurka, Cdc6, and

Ccne1 [46, 47]), and DNA damage response and repair process (27 out of 84, such as Rad51c, Mcm10,
and Brca2 [48–50]), which were upregulated in Ctl
reprogramming from S1 to S2, but downregulated by
Jaki-treatment at S2 (Fig. 3b–upper right and bottom,
Table 1). In addition, our RNA-seq analysis identified
35 and 130 genes at S1 and S2, respectively, which
were detectable exclusively in Ctl reprogramming but
absent under Jaki-treatment (Fig. 3c). GO analysis of
these two groups of genes also identified similar biological events including meiosis, spermatogenesis, and
oogenesis (Fig. 3c, Additional file 6). Some of these
JAK/STAT3-dependent genes identified such as Stra8,
Mael, and Sohlh2 are essential for the proper differentiation of germline stem cells (GSCs) both in drosophila and mammals [51–54].

Wang et al. BMC Genomics (2018) 19:183
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Fig. 3 JAK/STAT3 Signaling Controls the Activation of Key Genes for Germ Cell Development but Not Initial MET Transition in Reprogramming. a
Pie charts for summarized GO-terms using DEGs downregulated between Ctl and Jaki treatments at S2. The number of DEGs with GO terms vs.
the total number of DEGs was shown under the chart. b Venn Diagrams for DEGs from specific GO-terms upregulated from S1 to S2 under Ctl
reprogramming condition but downregulated at S2 by Jaki-treatment compared with the Ctl. Upper left: DEGs from meiotic GO-terms, upper
right: DEGs from mitotic GO-terms, bottom: DEGs from DNA damage/repair GO-terms. c Number of genes detected exclusively under either
DMSO or Jaki treatment at S1 and S2 and their relevant GO-terms (FDR < 0.1). d qPCR analysis for MET markers to reprogrammed cells collected
at two different reprogramming conditions and stages, with the expression in non-reprogrammed OG-MEFs set as the control. Bars represent
mean ± SD from three independent biological repeats. **: p < 0.01. e Heatmap of FPKM values of core epithelial/mesenchymal marker genes inreprogrammed cells at two different stages and conditions. The relative abundance is represented by color (blue, lower abundance; red, higher
abundance), as indicated by the color key

Previous study in mouse ESCs using chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-seq) has identified thousands of gene loci
directly bound by STAT3 [55]. We therefore asked
whether the JAK/STAT3-dependent genes in reprogramming are directly targeted by STAT3, by comparing our

data with the processed STAT3 ChIP-seq data [55], and
with some additional STAT3 targets from re-analysis
[35]. We found that more than 1/3 of the JAK/STAT3dependent spermatogenesis/DNA repair genes upregulated in reprogramming are bound by STAT3, such as
Brca2, Mael, Dmrt1, Chek2, etc., so is the case for

Wang et al. BMC Genomics (2018) 19:183
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Table 1 Common Genes from Three Categories of Biological
Processes Upregulated from S1 to S2 in Ctl Reprogramming but
Downregulated at S2 by Jaki-Treatment Compared with the
DMSO Ctl
GO-Biological Processes
Spermatogenesis and
Meiotic Cell Cycle

Mitotic Cell
Cycle

DNA Damage
and Repair

Aurka

Aurka

Ash2l

Brca2

Blm

Blm

Ccnb1

Brca2

Brca2

D1Pas1

Bub1

Cdc5l

Dmrt1

Ccnb1

Chaf1b

Dnmt3a

Ccne1

Chek2

Dnmt3l

Ccnf

Dna2

Herc4

Cdc5l

Eef1e1

Hist1h1t

Cdc6

Fanci

Hsf2

Chaf1b

Fancm

Hsf2bp

Chek2

Mael

Mael

Dna2

Mcm10

Rad51c

Esco2

Rad17

Rpl10l

Fanci

Rad51c

Setx

Ing5

Rnf138

Sirt1

Kif20b

Setx

Sohlh2

Kif2c

Sgk1

Sox17

Mcm10

Sirt1

Syce1

Mcm2

Smarcad1

Syce2

Mcm4

Tex15

Sycp1

Mybl2

Ticrr

Tcfl5

Nasp

Tipin

Tdrd12

Nol8

Trim28

Tex11

Nup37

Ube2t

Tex15

Orc6

Ung

Tex19.1

Rad17

Usp28

Tex40

Ska1

Usp7

Tyro3

Spc25

–

Uba1y

Ssbp1

–

–

Syce1

–

–

Syce2

–

–

Sycp1

–

–

Ticrr

–

–

Tipin

–

GO Gene Ontology Analysis. The STAT3 Direct Targets Are Marked
with bold

nearly 1/3 of the upregulated mitotic cell cycleassociated genes such as Ccne1, Mybl2, Cdc6, etc.
(Table 1). Taken together, these data strongly indicate
a specific role by JAK/STAT3 to activate genes regulating gametogenesis, meiotic, and mitotic cell cycle
events in reprogramming.

JAK/STAT3 activity does not affect mesenchymal to
epithelial transition in reprogramming

Blocking the MET process during reprogramming
inhibits the induction of SSEA-1+ or Oct4-GFP+
colonies [2, 3]. Interestingly, it has been shown that in
carcinogenesis STAT3 stimulates epithelial to mesenchymal transition, an opposite process of MET, by upregulating key mesenchymal genes Snai1, Snai2, and Twist
[56]. We wondered whether blocking STAT3 signaling
might negatively impact the MET progress in reprogramming. Quantitative PCR (qPCR) analysis for MET
marker genes revealed that compared to nonreprogrammed OG-MEFs, both S1 and S2 cells showed
significant downregulation of mesenchymal markers
including Snai1, Snai2, Cdh2, Twist1, and drastic upregulation of epithelial marker E-cadherin/Cdh1(Fig. 3d).
However, Jaki-treatment at either stage had no obvious
effect on the expression of these genes (Fig. 3d). This
indicates a successful MET transition in reprogramming
regardless of disturbed JAK/STAT3 activity. However,
two mesenchymal markers (Zeb2 and Twsit1) in Ctl
reprogramming condition were further downregulated at
S2 than at S1 (Fig. 3d). We then explored the reported
core mesenchymal and epithelial genes [57, 58] detected
in our RNA-seq. We found that many of these
mesenchyme-associated genes were downregulated from
S1 to S2 in both Ctl and Jaki-treatment (Fig. 3e). The
expression changes of core epithelial genes from S1 to
S2 are more complicated, with some epithelial markers
upregulated from S1 to S2 in Ctl reprogramming (such
as Epcam and Rlbp1), while some others (such as Krt14,
− 17, and Ocln) downregulated (Fig. 3e). These are in
agreement with the previous reports that activation of
Epcam is a marker for complete pluripotency at latereprogramming stage [4], whereas both Krt14 and − 17
are highly expressed at intermediate-stage but downregulated at late-reprogramming stage [9]. Blocking JAK/
STAT3 activity resulted in downregulation of some epithelial markers at S2 including Otx2, Mertk, Mift, and
Rlbp1, compared with the Ctl (Fig. 3e). Thus, these data
show that JAK/STAT3 activity does not negatively impact the initial MET process in reprogramming. On the
contrary, it stimulates the expression of some epithelial
markers at late-stage reprogramming. In addition, our
data also indicate that the expression of many core mesenchymal genes is further downregulated in latereprogramming stage (Fig. 3d, e). This may be important
for the stabilization of the reprogrammed iPSC state.
JAK/STAT3 signaling regulates proper activation of the
Dlk1-Dio3 imprinted region and key pluripotent genes

The activation of maternally expressed lincRNA cluster
Gtl2-Rian-Mirg in the Dlk1-Dio3 imprinted region is essential for full pluripotency establishment [15–17]

Wang et al. BMC Genomics (2018) 19:183
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(Additional file 1). We wondered whether JAK/STAT3
regulates the imprinting of the Dlk1-Dio3 region and
Gtl2-Rian-Mirg lincRNA expression. 60 lincRNAs with
significant expression changes were identified by our
RNA-seq analysis (Table 2). We found both Gtl2 (also
known as Meg3) and Mirg are among the 25 lincRNAs
downregulated at S2 in Jaki-treatment compared with
the Ctl (Fig. 4a, Table 2). qPCR analysis confirmed this
finding and further revealed that all three maternally
expressed lincRNAs in the Dlk1-Dio3 region were indeed downregulated at S2 by Jaki-treatment (Fig. 4b).
Interestingly, examining the STAT3 ChIP-seq data also
revealed the Gtl2/Meg3 gene as a direct target of STAT3
[35, 55] (Table 2).
The pluripotent factor Dppa3 is indispensable for
proper imprinting of the Dlk1-Dio3 region in reprogramming, through antagonizing hypermethylation of
IG-DMR by Dnmt3s [19]. We wondered whether JAK/
STAT3 activity regulates Dppa3 expression in

reprogramming. Out of the genes significantly downregulated at S2 in Jaki-treatment compared with the Ctl, we
identified some key pluripotent genes, such as Nanog,
Prdm14, Sall4, Tbx3, Tet1, Tfcp2l1, and miR92–2, which
belongs to the pluripotent miRNA cluster 106a-363
[59–61] (Fig. 4c, Additional file 4). Interestingly, RNAseq revealed that Dppa3 mRNA is only detectable in Ctl
reprogramming but not in Jaki-treatment at S2 (Fig. 4c).
We also found that two other Dppa family genes (Dppa2
and Dppa5a) were significantly downregulated by Jakitreatment (Fig. 4c). qPCR analysis confirmed that while
the expression of Dapp2, − 3, − 4, and -5a were all upregulated in Ctl reprogramming, their expression were
significantly inhibited by Jaki-treatment (Fig. 4d). This
correlates well with the previous studies [35, 55] showing that Dppa3, along with 22 out of the 34 JAK/
STAT3-depdendent pluripotent genes identified in Fig. 4c
and d, are direct STAT3 targets (Fig. 4e). Furthermore,
among the 34 JAK/STAT3-depdendent pluripotent genes,

Table 2 lincRNAs with Significant Expression Changes as Determined by RNA-seq Analysis
Jaki-S2 vs. DMSO-S2

Jaki-S1 vs. DMSO-S1

DMSO-S2 vs. DMSO-S1

Jaki-S2 vs. Jaki-S1

Up

Down

Up

Down

Up

Down

Up

Down

B230217O12Rik

H19

–

H19

2310031A07Rik

H19

2810429I04Rik

H19

Cep83os

1700001L05Rik

–

Gm26809

2810429I04Rik

1500026H17Rik

4732463B04Rik

3300005D01Rik

Gm15675

1700018B24Rik

–

Lncenc1

Epb41l4aos

1600025M17Rik

4930509G22Rik

6330403K07Rik

Gm20732

1700019E08Rik

–

Platr20

EU599041

2610035D17Rik

Gm19705

9030622O22Rik

Gm26569

1700057H21Rik

–

Platr4

Gm17275

4930431F12Rik

Gm807

Gm16211

Gm807

2210417A02Rik

–

–

Gm27010

Gm10660

–

Gm26809

Mirt1

2410018L13Rik

–

–
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Fig. 4 JAK/STAT3 Controls Proper Imprinting of the Dlk1-Dio3 Region and the Expression of Key Pluripotent Genes. a Expression fold change from
RNA-seq analysis for significantly downregulated lincRNAs in Jaki vs. DMSO for S2 reprogrammed cells. Genes exclusively detected in DMSO but
not Jaki-condition were also shown. b qPCR analysis of Gtl2-Rian-Mirg gene expressions in two different reprogramming conditions and stages.
R1-ESC was used as the control. Bars represent mean ± SD from three independent biological repeats. *: p < 0.05, **: p < 0.01. c Expression fold
change from RNA-seq analysis for pluripotent genes significantly downregulated between Jaki- vs. Ctl-treatment at S2. Genes detected exclusively
in Ctl but not in Jaki-treatment were also shown. Socs3 expression was shown as an indictor for inhibited STAT3 activity. d qPCR analysis of key
pluripotent gene expression under two different reprogramming conditions and stages. R1-ESC was used as the control. Bars represent mean ±
SD from three independent biological repeats. eOct4, eSox2: endogenous Oct4 and Sox2. Arrowhead: expression not detected. **: p < 0.01. e Venn
Diagram depicting the relationship among the pluripotent genes significantly downregulated between Jaki- vs. Ctl-treatment at S2, the STAT3
direct targets, and the makers specific for either naïve-state pluripotent ESCs or primed-state EpiSCs

7 (including the germline markers Dppa3 and Stra8) are
naïve-state ESC-specific [62, 63], with 4 out of these 7
genes (Dppa3, Fbxo15, Fgf4, and Tbx3) being direct targets of STAT3 (Fig. 4e). Interestingly, we also found that
the expression of 3 primed-state EpiSC markers (Nodal,
Lefty1, and Lefty2) [62, 63] is JAK/STAT3-dependent (Fig.
4c), with these gene loci bound by STAT3 [55] (Fig. 4e).
This is consistent with the previous studies showing both
LIF and ACTIVIN/NODAL promote the propagation of
naïve-state ESCs, while NODAL signal does not affect
naïve ESC pluripotency in serum-free condition [64, 65].
Thus, the proper expression of Gtl2-Rian-Mirg lincRNAs
is regulated by JAK/STAT3 at late-reprogramming stage,

and this may be achieved through direct STAT3 binding
to Gtl2/Meg3 and through JAK/STAT3-dependent Dppa3
activation in reprogramming. In the meanwhile, JAK/
STAT3 promotes complete pluripotency establishment by
stimulating the activation of key pluripotent genes, including the naïve-state and germ cell specific markers.
JAK/STAT3 regulates expression of key histone modifiers
during reprogramming

Epigenetic changes during reprogramming are essential
to activate core pluripotent genes, and silence transgenes
and lineage commitment genes [4, 6, 8, 9]. We previously identified that JAK/STAT3 activates the expression
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of de novo DNA methyltransferase Dnmt3a, − 3b, − 3 l,
and suppresses the histone deacetylases (Hdacs) expression [29]. Our RNA-seq data agree with these findings
and further revealed an increased Hdac10 expression in
S2 in the presence of Jaki (Fig. 5a). In addition, we discovered an increased expression of histone/lysine acetyltransferases (Hats/Kats) including Hat1, Kat5, −6b, and
− 8 [66] from S1 to S2 in Ctl reprogramming (Fig. 5a).
Blocking JAK/STAT3 activity, however, downregulated
Hats/Kats including Hat1, Kat6b, and Ncoa3 [67, 68] at
S2 compared with the Ctl (Fig. 5a). A direct binding to
Hdac10, Hat1, and Ncoa3 gene loci in ESCs by STAT3
was also shown before [55]. These data thus indicate
that in addition to inhibition of Hdacs, JAK/STAT3 also
selectively stimulates Hats/Kats expression to promote
histone acetylation in reprogramming.
PRC2 mediated H3K27 trimethylation is necessary to
suppress core developmental genes for successful reprogramming [69]. Moreover, in ESCs, PRC2 antagonizes
hypermethylation of the Dlk1-Dio3 IG-DMR region by
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de novo Dnmt3s, and depletion of PRC2 components
Eed, Jarid2, or the major methyltransferase Ezh2 suppressed maternal Gtl2-Rian-Mirg expression, due to
hypermethylation of IG-DMR [20]. As we have observed
that JAK/STAT3 promotes the expression of both Gtl2Rian-Mirg lincRNAs and de novo Dnmts at S2 (Figs. 4b,
5a, and reference [29]), we wondered if JAK/STAT3
would also regulate PRC2 activity to ensure proper imprinting of the Dlk1-Dio3 region. In fact, RNA-seq data
and qPCR analyses revealed that the expression of most
PRC2 components including Eed, Rbbp4, Jarid2, Mtf2,
esPRC2p48, Suz12, and Ezh2 increased from S1 to S2 in
Ctl reprogramming (Fig. 5b, c). However, blocking JAK/
STAT3 significantly inhibited the expression of these
PRC2 components (except for Rbbp4 and Suz12) at S2
compared to the Ctl (Fig. 5b, c). On the other hand, the
expression of another PRC2 methyltransferases - Ezh1
decreased from S1 to S2 in Ctl reprogramming, and
Jaki-treatment inhibited this decrease (Fig. 5c). Interestingly, it was also reported that inhibiting Ezh1 in

Fig. 5 JAK/STAT3 Controls the Expression of Key Histone Modifiers. a Heatmap of FPKM value comparison for Dnmt, Hdac, and Hat/Kat genes
detected under two different treatments and reprogramming stages. The relative abundance is represented by color (blue, lower abundance; red,
higher abundance), as indicated by the color key. b Heatmap of FPKM value comparison for PRC2 component genes detected under two
different treatments and reprogramming stages. The relative abundance is represented by color (blue, lower abundance; red, higher abundance),
as indicated by the color key. c qPCR analysis of PRC2 component gene expressions in two different reprogramming conditions and stages.
R1-ESC was used as the control. Bars represent mean ± SD from three independent experiments. **: p < 0.01
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reprogramming stimulated human iPSC generation [8].
Previous STAT3 ChIP-seq analysis again revealed that
Eed, Ezh2, Jarid2, and Rbbp4 are direct targets of STAT3
[35, 55]. Taken together, these data strongly argue that
JAK/STAT3 stimulates PCR2 activity in latereprogramming stage, which correlates with the proper
expression of Gtl2-Rian-Mirg lincRNAs, an essential
event for complete pluripotency establishment.
JAK/STAT3 activity is crucial for activating pluripotent
DNA loci during reprogramming

To test the epigenetic modulation of pluripotent loci including Oct4, Nanog, and the Dlk1-Dio3 region by JAK/
STAT3, we employed the Jaki-treated pre-iPSCs reprogrammed from OG-MEFs and collected at S2. These
cells could be passaged continuously in the presence of
Jaki or a LIF-neutralizing antibody (LIFAb) and
remained largely GFP-, thus further validating the specificity of Jaki on inhibiting LIF/STAT3 signaling (Fig. 6a).
We asked whether removing the inhibition of JAK/
STAT3 could resume the halted reprogramming process.
Removing Jaki from the culture medium (LIF+ condition) led to a gradual conversion of GFP- colonies to
GFP+ in 3 weeks, while those colonies left in either Jaki
or LIFAb treatment remained GFP-, as confirmed by
fluorescence activated cell sorting (FACS) (Fig. 6a, b).
Previously we reported that these GFP- pre-iPSCs had
hypermethylated Oct4 and Nanog promoters [29]. Our
study here further revealed that the expressions of some
important genes responsible for DNA-demethylation in
reprogramming are JAK/STAT3-dependent, including
the DNA hydroxylase Tet1 that promotes Oct4 demethylation and activation [70, 71], and Dppa3 and PRC2
genes that prevent de novo methylation of Dlk1-Dio3 region [19, 69] (Figs. 4c-e, 5b, c). We therefore asked
whether removing JAK/STAT3 inhibition is necessary to
re-activate these loci. We extracted DNAs from the
FACS sorted cells and analyzed their methylation status
using bisulfite sequencing. We found that upon restoring
JAK/STAT3 signaling, the Oct4 and Nanog promoter
loci were completely demethylated in GFP+ cells,
whereas in cells kept in Jaki or LIFAb these regions still
remained hypermethylated (Fig. 6c, Additional file 7).
Interestingly, the GFP- cells under LIF-only condition
showed a partial demethylation for the Oct4 promoter
(Fig. 6c), indicating resumed but still incomplete reprogramming status in these cells. Importantly, restoring
JAK/STAT3 activity also led to decreased methylation of
IG-DMR in the GFP+ cells, while the cells kept in Jakior LIFAb-treatment still remained hypermethylated for
this region (Fig. 6d). Thus, JAK/STAT3 signaling is indeed a prerequisite for activation of key pluripotent genomic loci and the Dlk1-Dio3 region in reprogramming
by promoting their DNA demethylation.
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Previously we discovered an epigenetic role by JAK/
STAT3 for pluripotency establishment in reprogramming, through regulation of Dnmts and Hdacs [29].
Based on our study here, we propose an updated model
for JAK/STAT3 regulated naïve-state pluripotency establishment at late-stage reprogramming (Fig. 5d), where
JAK/STAT3-dependent stimulation of Tet1, Dppa3,
PRC2, and Hats/Kats expression and inhibition of Hdacs
expression promote the euchromatic state at pluripotent
loci such as Oct4, Nanog, and Dlk1-Dio3 for their full activation by OKSM and other pluripotent factors including STAT3, while JAK/STAT3-dependent de novo
Dnmt3s expression helps silence commitment genes and
OKSM transgenes. These, together with the JAK/
STAT3-stimulated activation of germ cell-specific genes,
promote the establishment of ground state, germline
transmission-capable
naïve-pluripotency
in
reprogramming.

Discussion
The LIF regulated JAK/STAT3 pathway is important for
naïve-state pluripotency establishment across species for
iPSC generation [72]. Although many downstream targets of STAT3 have been reported, the complete understanding of JAK/STAT3 mediated pluripotency
establishment has not been achieved. We performed
RNA-seq to analyze JAK/STAT3 mediated reprogramming and identified biological events and DEGs specifically regulated by JAK/STAT3 activity during the iPSC
induction process. We found that during late-stage reprogramming, JAK/STAT3 signaling regulates gametogenesis events especially the spermatogenesis, mitotic/
meiotic cell cycle, and the DNA damage and repair
process - an essential process to ensure DNA integrity
during mitotic/meiotic cell division [73]. It is well established that in Drosophila, JAK/STAT activity is required
to for GSC maintenance in both testis and ovary [74–
77]. However, an understanding of the role by JAK/
STAT in GSC regulation in mammals is still limited [78,
79]. Our analysis revealed that JAK/STAT3 regulates the
expression of key germ cell developmental genes such as
Text19.1, Stra8, Mael, Sohlh2, Syce1/2, etc. In addition,
we also identified that JAK/STAT3 stimulates the expression of pluripotent transcription factors such as
Prdm14 and Dmrt1, which are critical for gonad development and GSC specification in mammals [80, 81].
Naïve-state pluripotency is important for the chimera
and germline chimera formation capability of mouse and
human ESCs/iPSCs [62, 63, 82–84]. The JAK/STAT3
regulated gametogenesis/meiotic events in reprogramming could be crucial for this germline chimerism capacity establishment. Our study provides valuable
mechanistic insight and information database for further
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Fig. 6 Restoring JAK/STAT3 Activity Promotes DNA Demethylation of Multi-Pluripotency Loci in pre-iPSCs. a Jaki-S2 pre-iPSC colonies cultured and
expanded in the presence of LIF plus Jaki (LIF+/Jaki+), LIFAb (LIF+/LIFAb+), or LIF-only (LIF+) for two weeks. Bar = 625 um. b FACS analysis for GFP+
and GFP- cells in expanded Jaki-S2 pre-iPSCs cultured in LIF containing medium supplemented with Jaki, LIFAb, or LIF-only condition for 3 weeks.
Numbers represent mean ± SD from three independent experiments. c DNA methylation of Oct4 promoter region measured by bisulfite sequencing
for samples described in b. Filled and open circles represent methylated and unmethylated CpGs, respectively. The percentage of total methylated
CpGs for the analyzed region was given on top of each dataset. d DNA methylation of IG-DMR region measured by bisulfite sequencing for samples
described in b. Filled and open circles represent methylated and unmethylated CpGs, respectively. The percentage of total methylated CpGs for the
analyzed region was given on top of each dataset. e The proposed model of JAK/STAT3 in promoting naïve-state pluripotency in reprogramming. LIF
activated JAK/STAT3 suppresses Hdacs and stimulates Hats/Kats, Tet1, Dppa3, and PRC2 genes for open chromatin formation in pluripotent and
gametogenic loci, promotes their full activation. Dppa3 and PRC2 inhibit de novo methylation of pluripotent loci by Dnmt3s. On the other hand, STAT3
activated Dnmt3s inhibit commitment genes and the OKSM transgenes, the silencing of which are needed for complete reprogramming. This leads to
the complete activation of pluripotent circuitry and establishment of naïve-state iPSCs

elucidation of reprogramming as well as meiotic processes specifically regulated by JAK/STAT3 signaling.
We discovered that JAK/STAT3 plays a critical role to
regulate the Dlk1-Dio3 imprinted region. Activation of
the maternally expressed Gtl2-Rian-Mirg lincRNAs in
this region serves as a key event for pluripotency establishment in late-stage reprogramming [15]. Recently it
was shown that Dppa3 is expressed only in iPSCs capable of chimera-formation and specifically blocks the
Dnmt3a mediated methylation of IG-DMR [19]. One of
the mechanisms therefore JAK/STAT3 regulates imprinting of the Dlk1-Dio3 region might be via JAK/

STAT3-dependent stimulation of Dppa3 expression.
However, other mechanisms may also play a role here.
The PRC2 components Ezh2, Eed, and Jarid2 were reported to prevent Dnmt3s from methylating the Dlk1Dio3 region, thus maintaining the expression of maternal Gtl2-Rian-Mirg in mouse ESCs [20]. We found that
blocking JAK/STAT3 activity inhibits the expression of
many PRC2 components. Thus JAK/STAT3 may also
regulate proper imprinting of the Dlk1-Dio3 region
through stimulating PRC2 activity. In accordance with
these findings, we discovered that removing Jaki in the
LIF+ medium promotes demethylation of IG-DMR, the
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region controlling Gtl2-Rian-Mirg expression. In
addition, histone acetylation of the Dlk1-Dio3 region
correlates with the activity of this region, and inhibiting
Hdacs activates the expression of Gtl2-Rian-Mirg in reprogramming [16]. We previously reported that JAK/
STAT3 activity downregulates the expression of Hdacs
during reprogramming [29] and here we further discovered that in addition to Hdacs, inhibition of JAK/STAT3
also blocks the expression of certain Hats/Kats. How
exactly JAK/STAT3 activity regulates the proper imprinting of the Dlk1-Dio3 region is certainly of high
interest and warrants future investigation.
We further identified that JAK/STAT3 activity regulates the activation of a number of key pluripotent factors such as the Dppa family genes. The expression of
Dppa3 is present only in iPSCs with chimera-forming
capacity, and blocking its expression results in the generation of pre-iPSCs only [19]. One possible mechanism
that JAK/STAT3 may regulate the expression of Dppa3
can be through promoting DNA demethylation at its
regulatory sequence, similar as what we demonstrated
here that JAK/STAT3 activity is essential for the demethylation of Oct4 and Nanog promoters in reprogramming. Additionally, one of the downregulated
pluripotent genes by Jaki-treatment - Tbx3 has been reported to prevent ESC differentiation through promoting
the expression of Dppa3 [85]. Exactly how JAK/STAT3
signaling activates these pluripotent genes to promote
complete reprogramming is currently under active investigation. Nevertheless our results correlate well with the
previous ChIP-seq analyses [35, 55] and strongly indicate
that an activated STAT3 elicits layers of regulatory
mechanisms over its targets, either directly or through
control of specific epigenetic modulators. Our analysis
demonstrates that JAK/STAT3 orchestrates events at
later-reprogramming stage from upregulation of gametogenesis, meiotic/mitotic, and DNA damage/repair processes, to stimulation of key pluripotent genes and
epigenetic regulators for complete pluripotency
establishment.

Conclusions
We performed transcriptome analysis to investigate the
genomic expression dynamics regulated by JAK/STAT3
activity during somatic cell reprogramming. We describe
JAK/STAT3-specific upregulation of biological events
such as gametogenesis and cell cycle processes in reprogrammed cells. We found that JAK/STAT3 does not
affect MET transition in reprogramming but regulates
the expression of some core mesenchymal/epithelial
markers, and describe key pluripotent transcription factors, epigenetic modulators, and non-coding RNAs regulated by JAK/STAT3. We show that JAK/STAT3 activity
is necessary for proper imprinting of the Dlk1-Dio3
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region, which is associated with the JAK/STAT3dependent stimulation of Dppa3 and PRC2 components
in reprogramming. We further demonstrate that JAK/
STAT3 activity is essential for promoting DNA demethylation of pluripotent loci including Oct4, Nanog, and
Dlk1-Dio3 regions at late-reprogramming stage. Our
data elucidate new mechanisms for JAK/STAT3 promoted pluripotency establishment in reprogramming,
which are valuable for improving the generation of
naïve-state iPSCs across species.

Methods
Chemicals and recombinant DNA constructs

The Jak inhibitor I (Jaki) was from EMD (Billierica, MA,
USA). LIF antibody (LIFAb) was from Santa Cruz (Santa
Crutz, CA, USA). Retroviral pMXs-mouse Oct4, Klf4,
Sox2, and c-Myc were from Addgene (Cambridge, MA,
USA). All constructs were verified by DNA sequencing.
RNA isolation, library construction and sequencing

Total RNA was isolated from reprogrammed cells with
different treatments using RNeasy Mini kit (Qiagen, Valencia, CA) and reverse transcribed using the SuperScript
III Reverse Transcription Kit (Invitrogen, Grand Island,
NY). The quality of Total RNA was examined with the
Aglient RNA 1000 Nano kit (Aglient Technologies,
Santa Clara, CA). rRNA was then removed by using
Ribo-Zero-rRNA Removal kit (Epicentre, Madison, WI).
500 ng of rRNA-depleted total RNA from each sample
was used to prepare the RNA sequencing library following the manufacturer’s instructions by SOLiD Total
RNA-seq Kit (Life Technologies, Grand Island, NY). Finally, sequencing libraries were quantified by using Agilent 2100 bioanalyzer and then barcoded, multiplexed,
and sequenced on a 5500xl Genetic Analyzer at the Center for Applied Genetics and Technology, University of
Connecticut. We obtained approximately 240 million sequencing reads with a read length of 75-bp from 8 samples. The raw FASTQ files and normalized gene
expression levels are available at Gene Expression Omnibus (GEO) (www.ncbi.nlm.nih.gov/geo) under the accession number GSE97261.
Data processing of RNA-seq

Sequencing reads were trimmed as previously described
[86]. Briefly, sequencing adapters were trimmed using
Cutadapt and low quality reads were pre-filtered by
FASTX-Toolkit before mapping. The quality of reads
after filtering was examined using fastQC. For mapping,
mouse genomic sequence and RefSeq gene coordinate
(GRCm38/mm10) were downloaded from the UCSC
genome browser. All filtered reads were aligned to
mouse reference genome by Tophat (v2.0.10) using
SAMtools (v0.1.18) AND Bowtie (v2.1.0) with default
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parameters [87, 88]. Individual mapped reads were
fed to Cufflinks (v1.2.1) [88] to contruct transcriptome models and any novel genes and transcripts that
did not fit the supplied gene models were also assembled. Cuffmerge [88] was used to converge individual
transcriptome to produce a master gene model. Then
Cufflinks was run to calculate Fragments Per Kilobase
of exon model per Million mapped fragments (FPKM)
by using RefSeq genes as reference [88]. A matrix of
Pearson correlation coefficient was created using R
Package, which was in turn used to create the heatmap. Differentially expressed genes between two
stages were identified using default parameters in
Cuffdiff [87]. We also included an additional bias detection and correction algorithm filter available in the
Cufflinks package to improve the accuracy of transcript abundance estimates. Genes were deemed differentially
expressed
between
subsequent
developmental stages if they showed a FDR (adjusted
p-value or q-value) of less than 0.05. Expression pattern clusters were generated by the K-means clustering algorithm using R.
Gene ontology, meta-analysis, and PCA analysis

Functional annotation enrichment analysis for Gene
Ontology (GO) and pathway analyses were conducted by
Database for Annotation, Visualization and Integrated
Discovery Bioinformatics Resource (DAVID) [89]. We
summarized all similar sub-GO terms and pathways into
an overarching term, and p-values are shown for the
representative terms. Principle component analysis
(PCA) was performed using the GeneXplain platform
(www.genexplain.com).
qPCR analysis

Total RNA were extracted using a RNeasy Extraction kit
(Qiagen, Hilden, Germany), reverse transcribed using a
iScript Reverse Transcription Kit (Bio-Rad, Hercules,
CA, USA) and PCR amplified with specific primers (Primer sequences available upon request). qRT-PCR was
performed using SYBR Green PCR Master Mix (BioRad) and the ABI 7500 Fast instrument, and data analyzed using the 7500 software version 2.0.2 provided
with the instrument. All values were normalized with
GAPDH as the internal control and relative mRNA expressions were quantified using either MEFs or R1-ESCs
as the reference, which is specified in each figure legend.
Data were analyzed with One Way ANOVA or the Student’s t-test.
Bisulfite sequencing

For bisulfite sequencing, genomic DNAs were extracted
and bisulfite converted using an EpiTeck Bilsulfite Kit
(Qiagen). Oct4 and Nanog promoter regions were
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amplified using PCR primers described previously [29].
Nested-PCR was used to clone the IG-DMR region, with
the first round amplification using primer pairs: 5′TAAGTGTTGTGGTTTGTTATGGGTA-3′ (forward)
and 5’-CCATCCCCTATACTCAAAACATTCT-3′ (reverse), and the second round using primer pairs: 5’TACCGGACTCAGATCT
TGGTTTGTTATGGGTA
AGTTTTATG (forward) and 3’-GTCGACTGCAGAATTC CTTCCCTCACTCCAAAAATTAAAA (reverse), with the bold letters indicate vector sequences
for fusion cloning. PCR were performed with Taq 2×
Master Mix (New England Biolabs, Ipswich, MA, USA)
and cloned using an In-Fusion HD Cloning System
(Clontech) into pIRES2-DsRed vector digested by BglII
and EcoRI (New England Biolabs). Clones were picked,
cultured in 5 ml LB medium with antibiotics overnight,
and plasmid DNAs were extracted using a Qiaprep Mini
Kit (Qiagen) and sequenced by regular Sanger DNA
sequencing.

Cell culture and reprogramming assay

Generation of Jaki-treated pre-iPSCs using retroviral
transduction and reprogramming medium was described previously [29]. The reprogramming medium
contains 1:1 mixture of KSR-ESC medium containing
76% KO-DMEM, 20% KSR, 1% 100× glutamax, 1%
100× non-essential amino acids, and 0.5× penicillin/
streptomycin (Invitrogen), and supplemented with 1%
100× β-mercaptoethanol and 1000 U/ml LIF (Millipore,
Billerica, MA, USA), and Serum-ESC medium with 76%
DMEM, 20% ESC-qualified FBS from Hyclone (Fisher Scientific, Pittsburg, PA, USA), 1% 100× glutamax, 1% 100×
non-essential amino acids, 0.5× penicillin/streptomycin,
1% 100× β-mercaptoethanol, and 1000 U/ml LIF. Induced
colonies were further expanded in the presence of Jaki in
ESC medium containing 76% KO-DMEM, 20% KSR, 1%
100× glutamax, 1% 100× non-essential amino acids, and
0.5× penicillin/streptomycin (Invitrogen), and supplemented with 1% 100× β-mercaptoethanol and
1000 U/ml LIF. For reprogramming assay, cells were
seeded at a density of 0.25 million cells per 24-wellplate pre-seeded with mitomycin C treated CD1 MEF
feeders on Day − 1. On day 0 the cells were infected
with retroviral OKSM, and medium replaced after
24 h. On day 2 the ESC medium containing 1 μM
Jaki or 0.5 μg/mL LIFAb were applied to all conditions except for the positive control wells. Media were
replaced every two days. GFP-expressing colonies
were scored between 2 to 3 weeks after initial viral
transduction under a Nikon fluorescence microscope,
or subjected to fluorescence-activated cell sorting
(FACS) for the percentage of GFP+ cells at the
UConn Bioservice Center.

Wang et al. BMC Genomics (2018) 19:183

Additional files
Additional file 1: Schematic representation of the Dlk1-Dio3 region at
mouse chromosome 12qF1. The Gtl2-Rian-Mirg lincRNAs are expressed
from the maternally inherited chromosome, while the protein coding
Dlk1, Rtl1, and Dio3 genes are expressed from the paternally inherited
chromosome. IG-DMR is paternally methylated but demethylated in maternal chromosome to control expression of the Gtl2-Rian-Mirg lincRNAs.
(PDF 61 kb)
Additional file 2: Cuffdiff Analysis Results Table of DEGs Between Ctl S2
vs. S1 (DMSO_S2 vs. S1), Jaki S2 vs. S1 (Jaki_S2 vs. S1), Jaki vs. DMSO at S1
(S2_Jaki vs. DMSO), and Jaki vs. DMSO at S1 (S1_Jaki vs. DMSO). (XLSX
829 kb)
Additional file 3: DAVID Analysis Table of Biological Processes (FDR <
0.05) for Common or Specific Up- or Down-regulated DEGs Between Ctl
reprogramming (DMSO_S2 vs. S1) and Jaki-reprogramming (Jaki_S2 vs.
S1). (XLSX 60 kb)
Additional file 4: DAVID Analysis Table of Biological Processes (FDR <
0.05) for Up- or Down-regulated DEGs Between Jaki vs. DMSO at S2.
(XLSX 28 kb)
Additional file 5: Table for DEGs listed in Spermatogenesis/Meiotic,
Mitotic, and DNA Repair GO-terms That Are Upregulated between Ctl S2
vs. S1 comparison but Downregulated at S2 in Jaki vs. Ctl comparison.
(XLSX 60 kb)
Additional file 6: Table for S1- or S2-specifically Expressed Genes under
DMSO Ctl or Jaki-Treatment at S1 or S2. (XLSX 102 kb)
Additional file 7: JAK/STAT3 Activity Is Needed to Activate Pluripotent
Loci in Reprogramming. DNA methylation of Nanog promoter region
measured by bisulfite sequencing for samples described in Fig. 6b. Filled
and open circles represent methylated and unmethylated CpGs,
respectively. The percentage of total methylated CpGs for the analyzed
region was given on top of each dataset. (PDF 322 kb)
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